Kymera Therapeutics Announces 2026 Clinical Milestones
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 13 2026
0mins
Kymera Therapeutics announced its anticipated 2026 preclinical and clinical milestones across its oral immunology pipeline. Key highlights: KT-621 BROADEN2 Phase 2b trial in AD ongoing, with data expected by mid-2027; KT-621 BREADTH Phase 2b trial in asthma initiated, with data expected in late-2027; KT-579 Phase 1 HV clinical trial expected to start in 1Q26, with data expected in 2H26; Advancing at least one new development candidate towards IND for a first-in-class, oral immunology program in 2026
Discover Tomorrow's Bullish Stocks Today
Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.
Sign up now to unlock expert insights and stay one step ahead of the market trends.
Analyst Views on KYMR
Wall Street analysts forecast KYMR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KYMR is 116.30 USD with a low forecast of 90.00 USD and a high forecast of 138.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
22 Analyst Rating
21 Buy
1 Hold
0 Sell
Strong Buy
Current: 71.160
Low
90.00
Averages
116.30
High
138.00
Current: 71.160
Low
90.00
Averages
116.30
High
138.00
About KYMR
Kymera Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system with a primary focus on immunology. The Company's targeted protein degradation (TPD) platform, which is a small molecule therapeutic modality that engages the body’s natural cellular recycling system to selectively eliminate disease-causing proteins. Its immunology programs target STAT6, IRF5 and IRAK4, each of which addresses targets within validated pathways, providing the opportunity to treat a broad range of diseases. It is developing KT-621 as part of its STAT6 program, which is being evaluated in a Phase I clinical trial in healthy volunteers. It is developing KT-579, which is an investigational, first-in-class, oral degrader of IRF5, a genetically validated transcription factor and a master regulator of immunity.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Kymera Stock Soars as Secretive Hedge Fund Acquires $172 Million Stake.
- Hedge Fund Activity: A secretive hedge fund focused on biotechnology has purchased shares of Kymera Therapeutics.
- Stock Performance: This acquisition occurred after Kymera Therapeutics' stock reached its highest level on record.
Continue Reading
S&P 500 Futures Decline in Pre-Market Session; Fermi and Broadcom Underperform
- Market Opening: U.S. stock markets are set to open in two hours.
- Lululemon Performance: Lululemon athletica inc. (LULU) saw a 9.1% increase in pre-market trading.
- Coeur Mining Performance: Coeur Mining Inc. (CDE) experienced a 4.6% rise in pre-market trading.
- Overall Market Sentiment: The pre-market gains indicate positive sentiment among investors for these companies.
Continue Reading